SCHEMBL2063900

SCHEMBL2063900

CCN(CC)Cc1sc(-c2nc(-c3ccc(S(=O)(=O)NCCN)cc3)no2)cc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
HDAC4 P56524 3/20 0.41
HDAC6 Q9UBN7 3/20 0.41
MAPT P10636 1/20 0.39
S1PR1 P21453 6/20 0.38
S1PR3 Q99500 5/20 0.38
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
ROCK1 Q13464 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
MMP2 P08253 2/20 0.36
MMP9 P14780 2/20 0.36
MMP8 P22894 2/20 0.36
MMP12 P39900 2/20 0.36
MMP13 P45452 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064418 0.91 HDAC4 (0.43) PIK3CDPIK3CBPIK3CGHDAC4HDAC6
SCHEMBL2064962 0.87 RARA (0.41) HDAC4HDAC6MAPTS1PR1S1PR3
SCHEMBL2064590 0.84 S1PR1 (0.41) HDAC4HDAC6MAPTS1PR1S1PR3
SCHEMBL2064694 0.84 S1PR1 (0.40) HDAC4HDAC6S1PR1S1PR3MMP2
SCHEMBL2065809 0.81 S1PR1 (0.40) MAPTS1PR1S1PR3RARARARB
SCHEMBL2064363 0.81 RARA (0.39) MAPTS1PR1S1PR3RARARARB
SCHEMBL2065052 0.81 RARA (0.40) MAPTS1PR1S1PR3RARARARB
SCHEMBL2066234 0.81 S1PR1 (0.45) HDAC4HDAC6MAPTS1PR1S1PR3
SCHEMBL2064223 0.78 RARA (0.59) S1PR1S1PR3RARARARBRARG
SCHEMBL2064096 0.78 S1PR1 (0.39) MAPTS1PR1S1PR3RARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 EP disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 PIK3CD 1122/4885PIK3CB 1363/4885PIK3CG 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.